Navigation Links
AAPS and FDA announce appointment of research fellow
Date:4/14/2009

ARLINGTON, VA. (April 6, 2009) The American Association of Pharmaceutical Scientists (AAPS) has announced the appointment of Demiana William Faltaos, Ph.D., to the position of Research Fellow at the Oak Ridge Institute for Science and Education (ORISE), where she will begin work this week to develop effective Alzheimer's disease-state models for a 2-year period. Dr. Faltaos' appointment comes at the end of a collaborative effort to recruit and screen scientific candidates for the position by AAPS and the U.S. Food and Drug Administration (FDA) as part of a Cooperative Research and Development Agreement (CRADA). The agreement was signed in December of 2007 by Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research at the FDA, and the Executive Director of AAPS, John Lisack Jr., CAE. The CRADA marks the first time that AAPS has contributed the funding for a specific research agreement.

"We are thrilled to have Dr. Faltaos become a part of this unique partnership between AAPS and the FDA," said Lisack. "Her research skills and experience will be put to great use on this project."

Dr. Faltaos received her Ph.D. in pharmacy from the "Ren Descartes" University of Paris V in May of 2006. Prior to accepting this appointment, she served as a Clinical Pharmacology and Clinical Pharmacokinetics researcher with Johnson & Johnson Pharmaceutical Research & Development in Belgium.

"Dr. Faltaos brings with her years of drug development experience and a strong background in modeling and simulation," said Joga Gobburu, Ph.D., Center for Drug Evaluation and Research, Office of Clinical Pharmacology, FDA. "The FDA is excited to embark on this important Critical Path project with new drugs under development that may modify disease progression, this CRADA will allow us to explore the benefits and risks of competing trial designs and analysis in order to discern disease-modification effects."

Under the terms of the CRADA, entitled "Enhancing Investigational New Drug Application (IND)/New Drug Application (NDA) Review Quality via Quantifying Prior Knowledge," AAPS and the FDA will look to advance current research by supporting the development of Alzheimer's disease-state models. These disease-state models will be implemented by the FDA to review clinical trial data for clinical pharmacology, as well as statistical and clinical reviews. Another goal is to use modeling and simulation (M/S) technology to improve efficiency in the drug product development process. AAPS members have agreed to provide its expertise in quantitative modeling and simulation, while FDA staff will provide working experience of disease-state model use.

The AAPS Executive Council voted to support funding of the initiative in May of 2006 and it has been in development since that point. AAPS has pledged to contribute $200,000 over the 2-year research period to ORISE to cover the research process and salary of Dr. Faltaos. One principal investigator from each organization will also be involved in the research, with Dr. Gobburu representing the FDA's Office of Clinical Pharmacology and Dr. Sandra Allerheiligen representing AAPS.


'/>"/>

Contact: Tom Huddleston
huddlestont@aaps.org
703-248-4744
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related medicine news :

1. Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis
2. Nu Skin Enterprises to Announce First Quarter 2009 Results
3. Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets
4. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
5. Gene Network Sciences Announces Brain Cancer Collaboration With M.D. Anderson
6. HCA Announces Offering of $500 Million Senior Secured First Lien Notes
7. RESOLVE: The National Infertility Association Announces Partnership With CutisPharma
8. PolicyStat Announces John C. Render has Joined company's Board of Advisors
9. Align Technology Announces ClearCorrects Filing of Notice of Voluntary Dismissal of Complaint
10. Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies
11. Dialysis Corporation of America Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Adolfson & Peterson Construction (AP) ... Ramsey County Medical Examiners Facility located in Saint Paul, Minn. A single story, ... scheduled to start in late 2017/early 2018. , Staffed by 20 full-time ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... OR (PRWEB) , ... July 21, 2017 , ... ... recent weeks Nature’s Tears® EyeMist®, the signature product of her research center at ... with the world’s largest population and the greatest number of sufferers of blindness. ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... TransPixel Volume ... between two clips in the FCPX timeline. This effect isolates horizontal and vertical lines ... this package contains either a rotating or flipping animation and can be changed using ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)...  Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing ... dosage forms of existing biologically active molecule. ... Subveta oral ... emulsifying formula, which is designed to prevent precipitation of the ... will provide fast onset of action and is designed to ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 /PRNewswire/ ... validate the use of MMprofiler with SKY92, the company,s ... (MM). In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will ... elderly patients. In a separate e-poster ...
Breaking Medicine Technology: